Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Free Radic Biol Med ; 211: 47-62, 2024 02 01.
Article in English | MEDLINE | ID: mdl-38043870

ABSTRACT

The suppression of tumor proliferation via cellular senescence has emerged as a promising approach for anti-tumor therapy. Tumor necrosis factor receptor-associated factor 2 (TRAF2), an adaptor protein involved in the NF-κB signaling pathway and reactive oxygen species (ROS) production, has been implicated in hepatocellular carcinoma (HCC) proliferation. However, little is currently known about whether TRAF2 promotes HCC development by inhibiting cellular senescence. Replicative senescence model and IR-induced mouse model demonstrated that TRAF2 expression was decrease in senescence cells or liver tissues. Depletion of TRAF2 could inhibit proliferation and arrest the cell cycle via activating p53/p21WAF1 and p16INK4a/pRb signaling pathways in HCC cells and eventually lead to cellular senescence. Mechanistically, TRAF2 deficiency increased the expression of mitochondrial protein reactive oxygen species modulator 1 (ROMO1) and subsequently activated the NAD+/SIRT3/SOD2 pathway to promote the production of ROS and cause mitochondrial dysfunction, which eventually contributed to DNA damage response (DDR). Our findings demonstrate that TRAF2 deficiency inhibits the proliferation of HCC by promoting senescence. Therefore, targeting TRAF2 through various approaches holds therapeutic potential for treating HCC.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Sirtuin 3 , Animals , Mice , Carcinoma, Hepatocellular/pathology , Cellular Senescence/genetics , Liver Neoplasms/pathology , NAD/metabolism , Reactive Oxygen Species/metabolism , Sirtuin 3/genetics , Sirtuin 3/metabolism , TNF Receptor-Associated Factor 2/genetics
2.
J Immunol ; 209(6): 1156-1164, 2022 09 15.
Article in English | MEDLINE | ID: mdl-35977799

ABSTRACT

There is no effective treatment for acute liver failure (ALF) except for an artificial liver support system (ALSS) and liver transplant. Bruton tyrosine kinase (Btk) plays important immunoregulatory roles in the inflammatory diseases, but its possible function in ALF remains to be characterized. In this study, we detected the phosphorylation level of Btk in ALF mouse liver and analyzed the protective effects of Btk inhibitor on survival rate and liver damage in ALF mouse models. We measured the expression levels of various inflammatory cytokines in the ALF mouse liver and primary human monocytes. In addition, we examined the expression of the NLRP3 inflammasome in mouse models with or without Btk inhibition. Clinically, we observed the dynamic changes of Btk expression in PBMCs of ALSS-treated patients. Our results showed that Btk was upregulated significantly in the experimental ALF mouse models and that Btk inhibition alleviated liver injury and reduced the mortality in these models. The protective effect of Btk inhibitors on ALF mice partially depended on the suppression of NLRP3 inflammasome signaling. Clinical investigations revealed that the dynamic changes of Btk expression in PBMCs could predict the effect of ALSS treatment. Our work shows that Btk inhibition is an effective therapeutic strategy for ALF. Moreover, Btk is a useful indicator to predict the therapeutic effect of ALSS on liver failure, which might have great value in clinical practice.


Subject(s)
Inflammasomes , Liver Failure, Acute , Agammaglobulinaemia Tyrosine Kinase/metabolism , Animals , Cytokines/metabolism , Disease Models, Animal , Down-Regulation , Humans , Inflammasomes/metabolism , Liver Failure, Acute/drug therapy , Liver Failure, Acute/metabolism , Mice , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
3.
Int Immunopharmacol ; 110: 109036, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35850053

ABSTRACT

BACKGROUND: Acetaminophen (APAP) overdose can cause severe liver injury and APAP-induced liver injury (AILI) is one of the leading causes of acute liver failure (ALF). Bruton's tyrosine kinase (BTK) is a key tyrosine kinase in immune responses, which plays an important role in many inflammatory diseases. However, its effect on AILI is still not clear. Here, we aimed to assess the effect of BTK on AILI and explore its underlying mechanism. METHODS: In our study, western blot and immunohistochemistry were used to detect the expression of BTK in AILI. The C57BL/6 mice were used to check the protective effect of BTK inhibition on AILI and the activation of BTK was confirmed in mice macrophages treated with APAP. Immunofluorescence, immunohistochemistry, oxygen consumption rate (OCR) detection, polymerase chain reaction (PCR), flow cytometry and western blot were used to determine the role of BTK in mitochondrial dynamics and function of macrophages and the underlying mechanisms in AILI. RESULTS: Our results showed that BTK upregulated in AILI. BTK inhibition protected mice from AILI and BTK was activated in mice macrophages in response to APAP. Mechanically, BTK inhibition promoted mitochondrial fusion and restored mitochondrial function through phospholipase C gamma 2 (PLCγ2)-reactive oxygen species (ROS)-Optic Atrophy 1(OPA1) pathway in macrophages and finally suppressed the release of proinflammatory cytokines. CONCLUSIONS: In conclusion, we found that BTK inhibition protected mice from AILI by restoring the mitochondrial function of macrophages through the improvement of the mitochondrial dynamic imbalance via PLCγ2-ROS-OPA1 signaling pathway, which indicated that BTK might be a potential therapeutic target of AILI.


Subject(s)
Chemical and Drug Induced Liver Injury, Chronic , Chemical and Drug Induced Liver Injury , Acetaminophen/pharmacology , Agammaglobulinaemia Tyrosine Kinase/metabolism , Animals , Chemical and Drug Induced Liver Injury/drug therapy , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury, Chronic/metabolism , Liver , Macrophages/metabolism , Mice , Mice, Inbred C57BL , Mitochondria/metabolism , Phospholipase C gamma/metabolism , Reactive Oxygen Species/metabolism
4.
Cell Prolif ; 54(6): e13040, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33942422

ABSTRACT

Acetaminophen (APAP) is a widely applied drug for the alleviation of pain and fever, which is also a dose-depedent toxin. APAP-induced acute liver injury has become one of the primary causes of liver failure which is an increasingly serious threat to human health. Neutrophils are the major immune cells in human serving as the first barrier against the invasion of pathogen. It has been reported that neutrophils patriciate in the occurrence and development of APAP-induced liver injury. However, evolving evidences suggest that neutrophils also contribute to tissue repair and actively orchestrate resolution of inflammation. Here, we addressed the complex roles in APAP-induced liver injury on the basis of brief introduction of neutrophil's activation, recruitment and migration.


Subject(s)
Acetaminophen/adverse effects , Analgesics, Non-Narcotic/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Neutrophils/drug effects , Animals , Cell Movement/drug effects , Chemical and Drug Induced Liver Injury/immunology , Chemical and Drug Induced Liver Injury/pathology , Humans , Neutrophils/immunology , Neutrophils/pathology
5.
Int Immunopharmacol ; 97: 107609, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33887577

ABSTRACT

Metabolic-associated fatty liver disease (MAFLD) is a common type of chronic liver disease characterized by excessive lipid accumulation in hepatocytes, but the pathogenesis is still unclear. Neutrophils, the most abundant immune cells in the human body, defend against pathogens and regulate the inflammatory response. Recent studies have indicated that excessive liver infiltration of neutrophils is a significant histological hallmark of MAFLD, and neutrophils and their derived granule proteins participate in different stages of MAFLD, including hepatic steatosis, inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. Hence, in this review, we summarize the role of neutrophils in the occurrence and progression of MAFLD and provide a perspective for the clinical application of neutrophils in MAFLD diagnosis and treatment.


Subject(s)
Carcinoma, Hepatocellular/immunology , Liver Cirrhosis/immunology , Liver Neoplasms/immunology , Neutrophils/immunology , Non-alcoholic Fatty Liver Disease/immunology , Animals , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Disease Models, Animal , Disease Progression , Hepatocytes/immunology , Hepatocytes/metabolism , Humans , Lipid Metabolism/immunology , Liver/cytology , Liver/immunology , Liver/pathology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/metabolism , Liver Cirrhosis/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Non-alcoholic Fatty Liver Disease/diagnosis , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/pathology
6.
J Cell Mol Med ; 25(2): 840-854, 2021 01.
Article in English | MEDLINE | ID: mdl-33263949

ABSTRACT

Hepatitis B virus (HBV) infection is a major public health problem. The high levels of HBV DNA and HBsAg are positively associated with the development of secondary liver diseases, including hepatocellular carcinoma (HCC). Current treatment with nucleos(t)ide analogues mainly reduces viral DNA, but has minimal, if any, inhibitory effect on the viral antigen. Although IFN reduces both HBV DNA and HBsAg, the serious associated side effects limit its use in clinic. Thus, there is an urgent demanding for novel anti-HBV therapy. In our study, viral parameters were determined in the supernatant of HepG2.2.15 cells, HBV-expressing Huh7 and HepG2 cells which transfected with HBV plasmids and in the serum of HBV mouse models with hydrodynamic injection of pAAV-HBV1.2 plasmid. RT-qPCR and Southern blot were performed to detect 35kb mRNA and cccDNA. RT-qPCR, Luciferase assay and Western blot were used to determine anti-HBV effects of MLN4924 and the underlying mechanisms. We found that treatment with MLN4924, the first-in-class neddylation inhibitor currently in several phase II clinical trials for anti-cancer application, effectively suppressed production of HBV DNA, HBsAg, 3.5kb HBV RNA as well as cccDNA. Mechanistically, MLN4924 blocks cullin neddylation and activates ERK to suppress the expression of several transcription factors required for HBV replication, including HNF1α, C/EBPα and HNF4α, leading to an effective blockage in the production of cccDNA and HBV antigen. Our study revealed that neddylation inhibitor MLN4924 has impressive anti-HBV activity by inhibiting HBV replication, thus providing sound rationale for future MLN4924 clinical trial as a novel anti-HBV therapy.


Subject(s)
Cyclopentanes/pharmacology , Hepatitis B virus/metabolism , Hepatitis B virus/pathogenicity , Hepatocyte Nuclear Factor 4/metabolism , Pyrimidines/pharmacology , Transcription Factors/metabolism , Animals , Blotting, Southern , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/metabolism , Cyclopentanes/therapeutic use , Hep G2 Cells , Hepatitis B virus/drug effects , Hepatocyte Nuclear Factor 4/genetics , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/metabolism , Mice , Pyrimidines/therapeutic use , RNA, Messenger/metabolism , Transcription Factors/genetics
7.
J Cell Mol Med ; 23(10): 6522-6529, 2019 10.
Article in English | MEDLINE | ID: mdl-31397086

ABSTRACT

As a cytoplasmic protein tyrosine kinase, Bruton's tyrosine kinase (Btk) is widely considered as a vital kinase in many aspects of different physiologic processes. It is engaged in many important signalling pathways related to the immune response, such as the B cell receptor pathway, pattern-recognition receptor pathway, and triggering receptor expressed on myeloid cell pathway. Recent studies have increasingly focused on the important role of Btk in various inflammatory diseases, which are related to Btk expression in myeloid innate immune cells, such as macrophages, dendritic cells and neutrophils. Although some investigations have explored the role of Btk in microbial infections, many aspects remain elusive, and some of the results are opposite and controversial. Considering the complicated and multiple roles of Btk in the immune system, we summarized the engagement of Btk signalling in various pathogenic microorganism infections, the possible mechanisms involved and its therapeutic potential in the control of infectious diseases.


Subject(s)
Agammaglobulinaemia Tyrosine Kinase/physiology , Infections/enzymology , Signal Transduction/immunology , Agammaglobulinaemia Tyrosine Kinase/genetics , Agammaglobulinaemia Tyrosine Kinase/metabolism , Bacterial Infections/enzymology , Bacterial Infections/immunology , Humans , Mycoses/enzymology , Mycoses/immunology , Parasitic Diseases/enzymology , Parasitic Diseases/immunology , Signal Transduction/genetics , Virus Diseases/enzymology , Virus Diseases/immunology
8.
Life Sci ; 223: 69-73, 2019 Apr 15.
Article in English | MEDLINE | ID: mdl-30831126

ABSTRACT

Pyroptosis is a novel programmed cell death form which is distinct from other types of cell death. As an inherently inflammatory process, it plays a vital role in cellular lysis and release of pro-inflammatory cytokines when hosts defend against infections. Recent studies have reported that pyroptosis was involved in liver diseases and had important functions in the progress and development of liver diseases. Here, we addressed the potential role of pyroptosis in liver diseases on the basis of brief introduction of the morphological characteristics, molecular and pathophysiological mechanisms of pyroptosis.


Subject(s)
Inflammasomes/metabolism , Liver Diseases/etiology , Pyroptosis/physiology , Animals , DNA Damage , Humans , Inflammasomes/genetics , Liver Diseases/genetics , Liver Diseases/metabolism , Liver Diseases/pathology , Pyroptosis/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...